Get the Stockscreener App
19.03
3.35%
-0.66
Overview
News
Price History
Option Chain
Financials
Why BAX Down?
Discussions
Forecast
Stock Split
Dividend History
Baxter International Inc stock is traded at $19.03, with a volume of 9.04M.
It is down -3.35% in the last 24 hours and down -4.42% over the past month.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
See More
Previous Close:
$19.69
Open:
$19.06
24h Volume:
9.04M
Relative Volume:
0.97
Market Cap:
$9.79B
Revenue:
$10.89B
Net Income/Loss:
$-241.00M
P/E Ratio:
-71.65
EPS:
-0.2656
Net Cash Flow:
$340.00M
1W Performance:
-7.76%
1M Performance:
-4.42%
6M Performance:
-19.16%
1Y Performance:
-45.41%
1-Day Range:
$18.46
$19.32
1-Week Range:
$18.46
$21.16
52-Week Range:
$17.40
$37.74
Baxter International Inc Stock (BAX) Company Profile
Name
Baxter International Inc
Sector
Industry
Phone
(224) 948-2000
Address
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
19.03 | 10.13B | 10.89B | -241.00M | 340.00M | -0.2656 |
|
ISRG
Intuitive Surgical Inc
|
497.42 | 176.23B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
174.21 | 50.22B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.08 | 41.28B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
258.28 | 37.50B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
44.39 | 37.20B | 27.43B | 1.27B | 1.01B | 1.5829 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Downgrade | Argus | Buy → Hold |
| Aug-04-25 | Downgrade | Stifel | Buy → Hold |
| Aug-01-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-26-25 | Resumed | Goldman | Buy |
| Feb-24-25 | Upgrade | Argus | Hold → Buy |
| Feb-20-25 | Resumed | Barclays | Overweight |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-30-24 | Initiated | Goldman | Neutral |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-03-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-15-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jun-24-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-18-22 | Reiterated | KeyBanc Capital Markets | Overweight |
| Feb-18-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-18-22 | Reiterated | Raymond James | Outperform |
| Feb-18-22 | Reiterated | Stifel | Buy |
| Feb-18-22 | Reiterated | UBS | Neutral |
| Feb-18-22 | Reiterated | Wells Fargo | Overweight |
| Feb-11-22 | Initiated | Goldman | Neutral |
| Jan-07-22 | Resumed | Citigroup | Buy |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-21 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-03-21 | Upgrade | Barclays | Equal Weight → Overweight |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-21 | Downgrade | UBS | Buy → Neutral |
| Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
| Oct-01-20 | Upgrade | Citigroup | Neutral → Buy |
| Sep-04-20 | Downgrade | Argus | Buy → Hold |
| Jun-24-20 | Initiated | Oppenheimer | Outperform |
| Mar-19-20 | Upgrade | Stifel | Hold → Buy |
| Mar-18-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-02-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-26-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Apr-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-19 | Upgrade | Citigroup | Neutral → Buy |
| Jan-02-19 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Nov-02-18 | Upgrade | Argus | Hold → Buy |
| Oct-16-18 | Initiated | Barclays | Underweight |
| May-17-18 | Resumed | Piper Jaffray | Overweight |
| Feb-06-18 | Reiterated | Citigroup | Neutral |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
View All
Baxter International Inc Stock (BAX) Latest News
Baxter International Inc (BAX) Trading Down 4.86% on Mar 2 - GuruFocus
Baxter International Inc. (BAX) Stock Analysis: Navigating Opportunities with a 6.20% Potential Upside - DirectorsTalk Interviews
DNB Asset Management AS Raises Stock Holdings in Baxter International Inc. $BAX - MarketBeat
Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & SuppliesDiversified Stocks - Finviz
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Nautilus Biotechnolgy (NAUT) and Delcath Systems (DCTH) - The Globe and Mail
Understanding Baxter International's Role in MedTech - www.whatjobs.com
Baxter International Inc.: - marketscreener.com
Baxter International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Baxter at Citi’s MedTech Day: Strategic Shifts Amidst Challenges - Investing.com
Baxter International Inc To Go Ex-Dividend On February 27th, 2026 With 0.01 USD Dividend Per Share - 富途牛牛
Siemens, Baxter, Hilton & more dividends 2026 • Vienna Stock Exchange - Wiener Börse
Ex-Dividend Reminder: MGE Energy, Labcorp Holdings and Baxter International - Nasdaq
Argus Research Maintains Baxter International Inc(BAX.US) With Hold Rating - 富途牛牛
Infusion Stand Market Is Going to Boom | BD • Baxter International • Smiths Medical - openPR.com
Baxter Investors Face a Test of Patience Amid Corporate Overhaul - AD HOC NEWS
Is Baxter International (BAX) Pricing In Its Turnaround After Years Of Share Price Weakness? - simplywall.st
Baxter International's $3 Billion Sales Base Facing Earnings Pressure - Smartkarma
Baxter is one of the S&P 500’s worst performers today. Earnings were brutal. - MSN
Baxter’s Ongoing Losses And Impairments Test The Investment Narrative - Yahoo Finance
Baxter International Inc. (BAX) Stock Analysis: Navigating Through Challenges with Strategic Resilience - DirectorsTalk Interviews
Is Baxter International Inc (BAX) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Baxter Hopes Recovery Under New CEO, Faces Near-Term Pressure - Citeline News & Insights
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading - Yahoo Finance
Patient Lifting Equipment Market is Going to Boom | Baxter International Inc., ICU Medical, Inc., B. Braun Melsungen AG - openPR.com
The Top 5 Analyst Questions From Baxter's Q4 Earnings Call - Finviz
Global Blood Plasma Derivatives Market Size Projected to Reach $104.30 Billion by 2033; Immunoglobulins Drive Robust 9.08% CAGR – SNS Insider - GlobeNewswire Inc.
Benefits of Device Connectivity - Baxter
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter (BAX) director Michael R. McDonnell files Form 3 showing 0 shares - Stock Titan
Anti-Venom Market 2026-2035 Top Key Playres: Baxter - openPR.com
Demystifying Baxter International: Insights From 4 Analyst Reviews - Benzinga
Baxter International Inc (BAX) Shares Up 3.99% on Feb 17 - GuruFocus
BAX: Goldman Sachs Lowers Price Target on Baxter International | - GuruFocus
Baxter Restructuring And Divestiture Plan Tests Turnaround And Valuation Case - Sahm
Baxter International (BAX) Returns To Quarterly Loss And Tests Earnings Recovery Narrative - Sahm
Aug Sectors: Is Baxter International Inc a potential multi baggerJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
UBS Maintains Neutral on BAX Baxter International Inc. Feb 2026 - Meyka
Baxter International Inc. (NYSE:BAX) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Pale Fire Capital Bets Big on Healthcare With a 2.07 Million Share Baxter International (BAX) Investment - Yahoo Finance
Baxter’s New Decentralized Model Tests Earnings And Valuation Expectations - Yahoo Finance
Baxter International Inc. (BAX) Stock Analysis: Navigating Challenges with a 9.31% Potential Upside - DirectorsTalk Interviews
Quarterly Trades: Does Baxter International Inc outperform in volatile marketsTrend Reversal & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Baxter International Stock Was Tumbling Today - AOL.com
Is Baxter International Inc. stock a top momentum playJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - mfd.ru
Is Baxter International Inc. stock a momentum leaderJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Baxter Overhaul Shifts To Decentralized Model As Recovery Timelines Extend - simplywall.st
Is Baxter International Inc. stock risky to hold nowProduct Launch & AI Based Buy and Sell Signals - mfd.ru
Baxter International Inc.: How a 90-Year Medtech Veteran Is Rebuilding Its Product Playbook - AD HOC NEWS
Baxter International (NYSE:BAX) Price Target Lowered to $17.00 at The Goldman Sachs Group - MarketBeat
A Quick Look at Today's Ratings for Baxter International Inc(BAX.US), With a Forecast Between $20 to $25 - 富途牛牛
Baxter is the S&P 500’s worst performer today. Earnings were brutal. - MSN
Baxter International Inc Stock (BAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):